Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older.
- People who have completed certain chemotherapy treatments (including taxane, platinum, vinca alkaloid-based chemotherapy, bortezomib, thalidomide, lenalidomide, ixazomib, or brentuximab vedotin) within the last 540 days, or who are currently on ongoing maintenance or palliative therapy using one of these drugs for more than 90 days.
- People who developed nerve damage (called chemotherapy-induced peripheral neuropathy, or CIPN) during or within 3 months of completing one of the listed chemotherapy drugs, confirmed by a specialist.
- People whose nerve damage causes at least one moderate or severe sensory symptom — such as numbness, tingling, prickling, stabbing, burning, or aching pain — either on the day of screening or in the week before.
- People who are able to communicate in English well enough to speak with study staff by phone and use the study app, website, and phone system (all of which are available in English only).
Who may not be able to join:
- People who are expected to start a new neurotoxic chemotherapy (such as platinum, taxane, vinca alkaloid, thalidomide, brentuximab vedotin, or arsenic trioxide) during the 13-week study period (note: this does not apply to people already on ongoing maintenance therapy as described above).
- People who have another nerve-related condition that could make it difficult to assess CIPN accurately, such as back or neck nerve compression (radiculopathy) or pre-existing nerve damage from another cause such as diabetes.
- People who are currently receiving treatment at a pain clinic specifically for CIPN-related pain.
- People who are currently participating in a different clinical trial for CIPN or pain treatment.
- Women who are currently pregnant.
- Women of childbearing potential who are unwilling to use an accepted form of contraception for the duration of the study (accepted methods include IUDs, hormonal implants such as Nexplanon, the contraceptive pill, contraceptive injections, or strict abstinence if that is already part of their current lifestyle).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Noah A Kolb, MD, University of Vermont
Phone: 802-847-4589
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The change in NTSS-6 between the run-in and the 12 week study period.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.